Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30353615)

  • 21. PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
    del Rivero J; Kohn EC
    Oncology (Williston Park); 2017 Apr; 31(4):265-73. PubMed ID: 28412778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers.
    Alruwaili MM; Zonneville J; Naranjo MN; Serio H; Melendy T; Straubinger RM; Gillard B; Foster BA; Rajan P; Attwood K; Chatley S; Iyer R; Fountzilas C; Bakin AV
    Cell Rep Med; 2024 Mar; 5(3):101434. PubMed ID: 38387463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
    Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
    PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of onconase in the therapeutic potential of PARP inhibitors in A375 malignant melanoma cells.
    Raineri A; Prodomini S; Fasoli S; Gotte G; Menegazzi M
    Biochem Pharmacol; 2019 Sep; 167():173-181. PubMed ID: 31185226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG; Robson ME
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
    Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
    J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
    Xiong J; Barayan R; Louie AV; Lok BH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.
    Francica P; Rottenberg S
    Genome Med; 2018 Dec; 10(1):101. PubMed ID: 30593284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
    Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
    Higuchi F; Nagashima H; Ning J; Koerner MVA; Wakimoto H; Cahill DP
    Clin Cancer Res; 2020 Apr; 26(7):1690-1699. PubMed ID: 31900275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
    Shah AP; Patel CN; Sureja DK; Sanghavi KP
    Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poly(ADP-ribose) polymerase inhibition: past, present and future.
    Curtin NJ; Szabo C
    Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells.
    Bellio C; DiGloria C; Foster R; James K; Konstantinopoulos PA; Growdon WB; Rueda BR
    Mol Cancer Res; 2019 Feb; 17(2):431-445. PubMed ID: 30401718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 37. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
    Rajawat J; Shukla N; Mishra DP
    Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting cancer stem cells in the tumor microenvironment: An emerging role of PARP inhibitors.
    Paul S; Sinha S; Kundu CN
    Pharmacol Res; 2022 Oct; 184():106425. PubMed ID: 36075511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
    Muvarak NE; Chowdhury K; Xia L; Robert C; Choi EY; Cai Y; Bellani M; Zou Y; Singh ZN; Duong VH; Rutherford T; Nagaria P; Bentzen SM; Seidman MM; Baer MR; Lapidus RG; Baylin SB; Rassool FV
    Cancer Cell; 2016 Oct; 30(4):637-650. PubMed ID: 27728808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.